Blurbs

Bio-Path Holdings (BPTH) Receives a Buy from H.C. Wainwright

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Bio-Path Holdings (BPTHResearch Report), with a price target of $9.00. The company’s shares closed yesterday at $3.30.

Chen covers the Healthcare sector, focusing on stocks such as Applied DNA Sciences, Veru, and Belite Bio, Inc. ADR. According to TipRanks, Chen has an average return of -23.0% and a 27.12% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bio-Path Holdings with a $9.00 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $5.28 and a one-year low of $2.68. Currently, Bio-Path Holdings has an average volume of 17.79K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Read More on BPTH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More